Posted by Michael Wonder on 10 Dec 2022
Health Canada authorises the Pfizer-BioNTech Omicron BA.4/BA.5 bivalent adapted COVID-19 booster for children 5 to 11 years of age
9 December 2022 - Today, Health Canada authorised the Pfizer-BioNTech Comirnaty Omicron BA.4/BA.5 bivalent adapted booster for use in children 5 to 11 years of age.
This is the first bivalent COVID-19 booster authorised for use in this age group that targets the original COVID-19 strain and the Omicron BA.4/BA.5 subvariants.
